Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma: Identification of New Therapeutic Targets
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 64
- 试验地点
- 1
研究概览
简要总结
The present project aims to elucidate the metabolic interactions within the tumor microenvironment of pancreatic adenocarcinoma, both in the primary tumor and in hepatic and pulmonary metastatic sites, as well as in circulating blood biomarkers.
Deciphering these complex interactions aims to identify exploitable vulnerabilities for predicting treatment efficacy or for guiding therapeutic strategies.
详细描述
Pancreatic adenocarcinoma (PDAC) remains one of the deadliest cancers, with survival rarely exceeding a few months and limited progress despite improved chemotherapy. Its poor prognosis is driven by late diagnosis, therapeutic resistance, and low responsiveness to targeted therapies and immunotherapy.
PDAC is characterized by a dense, immunosuppressive stroma and severe metabolic stress due to poor vascularization. Tumor progression relies heavily on stromal cells-such as cancer-associated fibroblasts and macrophages-as well as metabolic adaptations of cancer cells.
This project focuses on two key PDAC features to identify new biomarkers and therapeutic targets:
- Stromal cell prevalence
- Metabolic reprogramming
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years
- •Signed written informed consent specific to the PROMETAP study
- •Affiliation with a social security system
- •Treatment and follow-up performed at the Institut Paoli-Calmettes
- •Metastatic PDAC requiring biopsy as part of routine care (group1 and 2)
- •Prior treatment:
- •No previous chemotherapy for the "initial" group
- •No prior chemotherapy in the metastatic setting for the "Metastatic Relapse" group
- •Eligible for chemotherapy (ECOG < 2)
- •Non-Inclusion Criteria:
- •Contraindication to biopsy of the pancreatic tumor or a hepatic or pulmonary metastasis (group 1 and 2)
- •Absence of a metastasis accessible to biopsy (group1 and 2)
- •Concurrent treatment for another active cancer
- •Pregnant or breastfeeding women
- •Patients in emergency situations
- •5. Adult individuals under legal protection (guardianship, trusteeship, judicial protection) or unable to provide informed consent
排除标准
- 未提供